Life Sciences Companies To Steer Patents Away From New European Court
This article was originally published in Scrip
All healthcare and life sciences companies that responded to a survey by the law firm Hogan Lovells will opt their most important patents out of the European Unified Patent Court. The findings signal cautious joined up thinking on how companies will approach the new court, which is scheduled to launch in 2017.
Register for our free email digests: